Joyce University Expands Nursing Education to Students in Michigan and Kentucky
Over the past three years, Joyce University has steadily expanded beyond Utah, now serving students in 12 states, with Michigan and Kentucky as its newest additions in 2025. This continued growth underscores the university's commitment to meeting the increasing demand for skilled nurses by offering flexible, career-focused educational pathways tailored to diverse student needs.
'Joyce University is a community committed to improving access to high-quality education for aspiring nurses,' said Josh Knotts, interim President and CEO. 'Our vision is to create transformative learning environments that prepare graduates to make a positive impact on their communities. We are thrilled to bring this commitment and vision to students in Michigan and Kentucky.'
With this expansion, students in Michigan and Kentucky can access a range of pre-licensure programs, such as the 20-month Associate of Science in Nursing (ASN), the 3-year Bachelor of Science in Nursing (BSN), and the accelerated Bachelor of Science in Nursing (aBSN). Joyce University offers two post-licensure programs for those looking to further their nursing careers: the 4-semester online RN to BSN program and the 3-semester online MSN in Leadership program.
Joyce University's hybrid educational model blends online learning with immersive hands-on skill development at the Joyce Johnson Center of Simulation in Draper, Utah. Clinical placements are conducted locally within Michigan and Kentucky, providing practical experience within local communities.
Enrollment for Michigan and Kentucky students is now open, with the next cohort beginning in the Fall Semester on September 2, 2025.
For more information about Joyce University programs or employment opportunities, visit joyce.edu.
ABOUT JOYCE UNIVERSITY
Founded in 1979, Joyce University of Nursing and Health Sciences' mission is to prepare students to serve as competent professionals, to advance their careers, and to pursue lifelong learning. Located in Draper, Utah, Joyce University is proud to have helped thousands of students across the US graduate and launch lasting healthcare careers. With a recent expansion of its pre-licensure programs to select regional locations, including Arizona, Colorado, Idaho, Kentucky, Michigan, Missouri, Nevada, New Mexico, Ohio, Oregon, South Carolina, and Wisconsin, Joyce University's expansion enables aspiring nurses in these regions to access the same high-quality education and opportunities that have defined the institution for decades. Join them as they continue to shape the future of healthcare, one student at a time.
Joyce University is institutionally accredited by the Northwest Commission on Colleges and Universities (NWCCU) and programmatically accredited by the Accreditation Commission for Education in Nursing (ACEN) for the Associate of Science in Nursing degree program and by the Commission on Collegiate Nursing Education (CCNE) for the Bachelor of Science in Nursing and Master of Science in Nursing degree programs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
How 9 minutes of daily HIIT may improve kids' brain function and learning, according to research
When you buy through links on our articles, Future and its syndication partners may earn a commission. Kids' attention spans aren't exactly getting any longer. Some can't even make it to the end of a 10-second TikTok without swiping away. To be honest, I'm also guilty of this sometimes. But if you can hold their focus for nine whole minutes of exercise, scientists think they've found a little hack that could help children concentrate better in class. Researchers from the University of Eastern Finland studied how short bursts of physical activity could influence a child's ability to focus. They asked seven- to 13-year-olds to complete a simple nine-minute workout before sitting down to cognitive tests. The results? Kids who exercised performed better on tasks that required sustained attention and working memory compared to those who stayed seated. If you are a parent looking to move more and encourage your children to do the same, our guide to the best fitness trackers can help you keep track of your activity levels and stay motivated. What kind of exercise did the study use? The study found that nine minutes of high-intensity interval exercise (HIIE) can help children focus better and improve performance on cognitive tasks. For reference, this activity took place in a school setting before tests. The researchers suggest the boost in focus may come from the temporary increase in heart rate and blood flow, which delivers more oxygen and nutrients to the brain, along with the release of neurotransmitters that support alertness and cognitive function. If you are a parent and want to try using this at home to help your child focus, settle down after school, or tackle homework more easily, the principle is pretty flexible. You don't need a full PE class. Just nine minutes of fun, energetic high-intensity interval exercise (HIIE) that gets your child's heart rate up could make a difference. This could be a quick dance to a favorite song or two, a short obstacle course in the living room, or a few laps around the yard. It's important to note that this research does not provide a guaranteed solution for improving focus in all children, and every child's needs and circumstances are different. The study shows a potential benefit in a classroom setting, but individual results may vary. Still, making exercise a fun and regular part of family life can support both the body and mind. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button. More from Tom's Guide Here are 7 ways I get the most out of my Garmin watch when training for a race I do this quick chair exercise every day to beat back pain and strengthen my core while I work Forget running — I added power walking intervals to my walks and now I'm hooked Solve the daily Crossword
Business Wire
3 hours ago
- Business Wire
Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer
SÖDERTÄLJE, Sweden--(BUSINESS WIRE)--Anocca AB ('Anocca' or the 'Company'), a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK ~440 million (USD ~46 million) in financing. The additional capital will be used to drive the continued progress of VIDAR-1, Anocca's gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer, through early-stage clinical development, as well as progress Anocca's preclinical pipeline. The financing was led by Mellby Gård with strong support from AMF, Ramsbury and existing shareholders, alongside new investors. Recruitment is now open for Phase I of the multi-centre trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany and The Netherlands. Reagan Jarvis, co-founder and Chief Executive Officer of Anocca, said: 'We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.' Johan Andersson, Chairman of Mellby Gård, commented: 'We have been invested in Anocca throughout its preclinical development and are pleased to see the Company transition into a clinical stage biotech. We look forward to seeing Anocca help patients that have limited treatment options today with their innovative approach to T-cell therapies.' SEB Corporate Finance acted as financial advisor to Anocca on the finalisation of the transaction, and Mannheimer Swartling and HWF Advokater have acted as legal advisors. ENDS About Anocca Anocca is a fully integrated clinical-stage biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. The company has built a unique discovery engine that uses programmable human cells to recreate and manipulate T cell immunity. These proprietary technologies enable scaling of TCR-T cell therapy development, allowing the systematic generation of libraries of products that represent personalised treatments for the broad patient populations. Anocca currently has the broadest pipeline of TCR-T oncology cell therapy treatments. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and an in-house cGMP manufacturing and process development facility. Anocca's TCR-T cell therapies are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca's facilities in Södertälje, Sweden. 130+ staff from 40+ nations work at Anocca. About the VIDAR-1 clinical programme VIDAR-1 is designed as a multi-product umbrella trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma (PDAC). It will investigate up to 20 patients per product in a set of phase I/II studies. Phase I is currently conducted at eight sites in four countries with additional countries and sites in phase II. Patients will be eligible to enrol if they have an HLA, and KRAS mutation, matching an available product. More information about the clinical trial can be found at the EU's clinical trials website. About KRAS and PDAC Mutant KRAS is implicated in pancreatic, lung and colorectal cancers. G12V and G12D mutations in KRAS affect around 90% of pancreatic cancer patients. The five-year survival rate of patients with PDAC is less than 10% (1). Despite recent advances there are no definitive treatments for advanced patients at present (2). References 1. Rawla et al (2019). Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 10(1):10–27. doi: 10.14740/wjon1166 2. Hu & O'Reilly (2023). Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol 21, 7–24. doi: 10.1038/s41575-023-00840-w
Associated Press
4 hours ago
- Associated Press
Genflow Biosciences PLC Announces Company Update on Dog Trials
Genflow Advances World's First Longevity Gene Therapy Trial in Dogs with No Adverse Effects Reported LONDON, UK / ACCESS Newswire / August 18, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ('Genflow' or 'the Company'), the only publicly listed longevity company in Europe, provides an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs. The randomized, controlled trial, conducted with CRO Syngene, involves 28 beagles aged 10+ years. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects, while controls remain untreated. The dogs will now enter a five-month follow-up period expected to conclude in January 2026. The strategic goal of this proof-of-concept trial is to generate compelling preclinical data that will enable a licensing agreement with a leading Animal Health company. GF-1004 is a first-in-class gene therapy candidate targeting fundamental aging mechanisms shared by both dogs and humans. By intervening at the mitochondrial and epigenetic levels, GF-1004 offers the potential to not only extend lifespan, but also improve the quality of life in companion animals, a rapidly growing, high-value market segment. Study objectives are to: 1. Confirm feasibility of GF-1004 administration in the target population. 2. Validate safety and efficacy at the proposed administered dose. 3. Demonstrate multi-dimensional benefits relevant to both clinical outcomes and consumer appeal, including: Translational Potential Since dogs and humans share conserved aging pathways, success in this trial will provide a strong foundation for expansion into human health applications, unlocking additional markets in longevity therapeutics. Dr. Eric Leire, CEO of Genflow, commented: 'Now that all dogs have received the treatment without any adverse events, we've taken an important step in confirming the treatment's safety profile. We are fully focused on advancing GF-1004 to secure a partnership with an animal health company, combining scientific and commercial expertise to pave the way for a new class of therapeutic medicines for dogs. Our shared goal is to extend the healthspan of dogs, and we believe this study will demonstrate the safety and potential efficacy of GF-1004 while opening the door to broader applications of our proprietary platform in age-related diseases in both companion animals and, ultimately, in humans.' Contacts About Genflow Biosciences Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit and follow the Company on LinkedIn and X. DISCLAIMER The contents of this announcement have been prepared by, and are the sole responsibility of, the Company. This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words 'anticipate', 'believe', 'continue', 'could', 'estimate', 'expect', 'intend', 'may', 'might', 'plan', 'possible', 'potential', 'predict', 'project', 'seek', 'should', 'would' and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions. Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit SOURCE: Genflow Biosciences PLC press release
